JOIN MAILING LIST

PRESENTATION

PIPELINE

INVESTORS

VIDEO

ABOUT US

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles.

Oramed’s oral insulin is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.

In addition to oral insulin, the company’s proprietary POD™ technology can be used to orally administer a number of protein-based therapies, which are available only via injection.

PRESS RELEASES

Oramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study

May 18th, 2016|

All Primary Safety and Efficacy Endpoints Were Met; Conference Call Today […]

Oramed to Present at Oppenheimer Annual Israeli Conference

May 16th, 2016|

JERUSALEM, May 16, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), […]